↓ Skip to main content

Dove Medical Press

Article Metrics

Telavancin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA)

Overview of attention for article published in Therapeutics and Clinical Risk Management, March 2012
Altmetric Badge

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
7 Dimensions

Readers on

mendeley
24 Mendeley
Title
Telavancin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA)
Published in
Therapeutics and Clinical Risk Management, March 2012
DOI 10.2147/tcrm.s23247
Pubmed ID
Authors

Candace Hooper, Winter Smith

Abstract

Telavancin is a bactericidal lipoglycopeptide antibiotic that is structurally related to vancomycin. It demonstrates in vitro activity against a variety of Gram-positive pathogens including, but not limited to, methicillin-resistant Staphylococcus aureus (MRSA). Telavancin is currently FDA-approved for the treatment of complicated skin and skin-structure infections. Recently, two randomized clinical trials demonstrated the efficacy and safety of telavancin compared to vancomycin for the treatment of nosocomial pneumonia. Overall, telavancin has a favorable safety profile. However, mild gastrointestinal disturbances and reversible increases in serum creatinine were observed in clinical studies. Additional clinical studies are needed to evaluate telavancin's efficacy and safety in comparison to other antistaphylococcal agents for the treatment of infections such as bacteremia and endocarditis.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 24 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 24 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 4 17%
Student > Master 4 17%
Other 3 13%
Student > Ph. D. Student 3 13%
Student > Doctoral Student 2 8%
Other 2 8%
Unknown 6 25%
Readers by discipline Count As %
Medicine and Dentistry 7 29%
Agricultural and Biological Sciences 4 17%
Nursing and Health Professions 2 8%
Biochemistry, Genetics and Molecular Biology 2 8%
Immunology and Microbiology 1 4%
Other 2 8%
Unknown 6 25%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 March 2012.
All research outputs
#9,993,254
of 12,485,238 outputs
Outputs from Therapeutics and Clinical Risk Management
#761
of 922 outputs
Outputs of similar age
#84,822
of 119,421 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#9
of 13 outputs
Altmetric has tracked 12,485,238 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 922 research outputs from this source. They receive a mean Attention Score of 4.1. This one is in the 8th percentile – i.e., 8% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 119,421 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 14th percentile – i.e., 14% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 13 others from the same source and published within six weeks on either side of this one. This one is in the 23rd percentile – i.e., 23% of its contemporaries scored the same or lower than it.